Adela Cardones

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1191771/publications.pdf

Version: 2024-02-01

41	573	840776 11	642732 23
papers	citations	h-index	g-index

41	41	41	826
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the UnitedÂStates. Journal of Investigative Dermatology, 2018, 138, 2315-2321.	0.7	94
2	How I treat refractory chronic graft-versus-host disease. Blood, 2019, 133, 1191-1200.	1.4	70
3	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€"ABCD-10. JAMA Dermatology, 2019, 155, 448.	4.1	69
4	Preliminary Results on the Feasibility of Using ARFI/SWEI to Assess Cutaneous Sclerotic Diseases. Ultrasound in Medicine and Biology, 2015, 41, 2806-2819.	1.5	53
5	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clinics in Dermatology, 2020, 38, 702-711.	1.6	38
6	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology, 2020, 82, 1553-1567.	1.2	35
7	Subacute cutaneous lupus erythematosus and dermatomyositis associated with antiâ€programmed cell death 1 therapy. British Journal of Dermatology, 2019, 181, 580-583.	1.5	28
8	De novo belatacept in clinical vascularized composite allotransplantation. American Journal of Transplantation, 2018, 18, 1804-1809.	4.7	23
9	Updates on Merkel Cell Carcinoma. Dermatologic Clinics, 2019, 37, 489-503.	1.7	23
10	Pinch Purpura: A Cutaneous Manifestation of Systemic Amyloidosis. American Journal of Medicine, 2015, 128, e3-e4.	1.5	15
11	Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. PLoS ONE, 2018, 13, e0198074.	2.5	15
12	Th17 cell inhibition in a costimulation blockadeâ€based regimen for vascularized composite allotransplantation using a nonhuman primate model. Transplant International, 2020, 33, 1294-1301.	1.6	10
13	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. Journal of Investigative Dermatology, 2021, 141, 924-927.e2.	0.7	10
14	Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. JAMA Dermatology, 2018, 154, 589.	4.1	9
15	Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. British Journal of Dermatology, 2022, 187, 126-127.	1.5	9
16	Disseminated Cutaneous Cytomegalovirus Infection Following Total Body Electron Beam Irradiation for Mycosis Fungoides. JAMA Dermatology, 2015, 151, 1380.	4.1	8
17	Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatology, 2016, 152, 227.	4.1	8
18	Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update. Current Dermatology Reports, 2019, 8, 219-233.	2.1	7

#	Article	IF	Citations
19	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatology, 2019, 155, 833.	4.1	6
20	Long-term improvement of recalcitrant Darier disease with photon and electron beam radiation therapy. JAAD Case Reports, 2018, 4, 1062-1064.	0.8	5
21	Management of Infectious Emergencies for the Inpatient Dermatologist. Current Dermatology Reports, 2021, , 1-11.	2.1	5
22	Long-term improvement of recalcitrant Hailey-Hailey disease with electron beam radiation therapy: Case report and review. Practical Radiation Oncology, 2018, 8, e259-e261.	2.1	4
23	Highâ€dose intravenous immunoglobulin as adjuvant treatment for grade <scp>IV</scp> acute cutaneous graftâ€versusâ€host disease. British Journal of Dermatology, 2019, 181, 869-871.	1.5	4
24	Analysis of clinical characteristics of drug-induced cutaneous lupus erythematosus in men. Journal of the American Academy of Dermatology, 2020, 83, 1455-1457.	1.2	4
25	Concepts and controversies in the treatment of cutaneous lichen planus. Italian Journal of Dermatology and Venereology, 2017, 152, 607-614.	0.2	4
26	Analysis of Factors Affecting Shear Wave Speed in in vivo Skin. , 2019, , .		3
27	Externally applied high-dose-rate brachytherapy for deeply invasive cutaneous squamous cell carcinoma in an older patient. Practical Radiation Oncology, 2016, 6, e141-e144.	2.1	2
28	Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide. Current Dermatology Reports, 2019, 8, 208-218.	2.1	2
29	Comparison of Deep Learning and Classical Image Processing for Skin Segmentation. , 2019, , .		2
30	Opportunistic cutaneous fungal infections in the inpatient setting. International Journal of Dermatology, 2016, 55, e223-6.	1.0	1
31	Cost of Inpatient Care of Patients With Pemphigus in the United States. JAMA Dermatology, 2016, 152, 629.	4.1	1
32	Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients?. British Journal of Dermatology, 2017, 177, 1145-1147.	1.5	1
33	Timing and Number of Cutaneous Squamous Cell Carcinomas in Transplant Recipients. JAMA Dermatology, 2018, 154, 727.	4.1	1
34	The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients. Clinical and Experimental Dermatology, 2019, 44, 265-269.	1.3	1
35	Semi-automated weak annotation for deep neural network skin thickness measurement. Ultrasonic Imaging, 2021, 43, 167-174.	2.6	1
36	Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.. Journal of Clinical Oncology, 2018, 36, e22095-e22095.	1.6	1

#	Article	IF	Citations
37	Ruxolitinib for the treatment of steroid refractory pediatric chronic graftâ€versusâ€host disease. Pediatric Dermatology, 2022, , .	0.9	1
38	Early-stage melanoma and hematopoietic stem cell transplantation outcomes. Journal of the American Academy of Dermatology, 2019, 80, 786-788.	1.2	0
39	Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient. , 2021, , 1577-1594.		0
40	Rashes to Recognize in the Immunocompromised Transplant Patient: Focus on the Solid Organ Transplant Recipient. , 2021, , 1-19.		0
41	Response to â€˜Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotinâ€™ :reply from authors. British Journal of Dermatology, 2022, , .	1.5	0